Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNL-NM-CAB004
- Development stage
- Preclinical
- Lead developer
- Genencell
- Modality
- Small Molecules
01
Overview
GNL-NM-CAB004 is a natural product-based drug candidate being developed by the South Korean biotechnology company Genencell for the treatment of obesity. Classified as a natural product medicine (천연물 의약품), it is derived from biological sources rather than being a purely synthetic small molecule. While the specific botanical or biological source and the exact molecular mechanism of action have not been publicly disclosed, the candidate is part of Genencell's specialized pipeline focusing on standardized natural extracts for metabolic and infectious diseases. It is currently in early-stage development, moving through efficacy testing and domestic clinical evaluation in South Korea.
Beyond the preview
Go deeper on GNL-NM-CAB004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNL-NM-CAB004.